MX2017014002A - Moléculas de direccionamiento del sistema de secreción tipo iii . - Google Patents

Moléculas de direccionamiento del sistema de secreción tipo iii .

Info

Publication number
MX2017014002A
MX2017014002A MX2017014002A MX2017014002A MX2017014002A MX 2017014002 A MX2017014002 A MX 2017014002A MX 2017014002 A MX2017014002 A MX 2017014002A MX 2017014002 A MX2017014002 A MX 2017014002A MX 2017014002 A MX2017014002 A MX 2017014002A
Authority
MX
Mexico
Prior art keywords
molecules
type iii
secretion system
iii secretion
specifically bind
Prior art date
Application number
MX2017014002A
Other languages
English (en)
Inventor
Brendan P Eckelman
John C Timmer
Quinn Deveraux
Hollands Andrew
Original Assignee
Inhibrx Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Lp filed Critical Inhibrx Lp
Publication of MX2017014002A publication Critical patent/MX2017014002A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Esta invención esta relacionada en general a moléculas que se unen específicamente a proteínas V-tip bacterianas del sistema de secreción tipo III de bacterias Gram negativas tales como PcrV de Pseudomonas aeruginosa; más específicamente, esta invención se relaciona con moléculas que bloquean la inyección de moléculas efectoras de células objetivo; esta invención también se relaciona con moléculas de la presente invención son monoespecificas o multiespecificas y pueden unirse a su antígeno objetivo en una manera monovalente o multivalente; la inversión también está relacionada en general a moléculas se unen específicamente a proteínas de la superficie celular tales como OprI, y a métodos para usar estas moléculas en una variedad de indicadores terapéuticos de diagnóstico y/o profilácticas.
MX2017014002A 2015-05-01 2016-05-02 Moléculas de direccionamiento del sistema de secreción tipo iii . MX2017014002A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562155967P 2015-05-01 2015-05-01
US201562254992P 2015-11-13 2015-11-13
PCT/US2016/030429 WO2016179101A2 (en) 2015-05-01 2016-05-02 Type iii secretion system targeting molecules

Publications (1)

Publication Number Publication Date
MX2017014002A true MX2017014002A (es) 2018-08-01

Family

ID=57205652

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014002A MX2017014002A (es) 2015-05-01 2016-05-02 Moléculas de direccionamiento del sistema de secreción tipo iii .

Country Status (15)

Country Link
US (2) US10344078B2 (es)
EP (1) EP3288974B1 (es)
JP (1) JP6966330B2 (es)
KR (1) KR20180020142A (es)
CN (1) CN107922482A (es)
AU (1) AU2016257751B2 (es)
BR (1) BR112017023378A2 (es)
CA (1) CA2984628C (es)
ES (1) ES2846881T3 (es)
HK (1) HK1250991A1 (es)
IL (1) IL255329B (es)
MX (1) MX2017014002A (es)
RU (1) RU2759949C2 (es)
WO (1) WO2016179101A2 (es)
ZA (1) ZA201707404B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490686A (zh) * 2019-01-07 2021-10-08 拜科托莱夫有限公司 病原体结合蛋白
SG11202111927QA (en) * 2019-05-08 2021-11-29 2Seventy Bio Inc Cll-1 targeted immunotherapies
WO2021119832A1 (en) * 2019-12-20 2021-06-24 Kisoji Biotechnology Inc. Polypeptides, protein complexes and method for making same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094951A (en) * 1988-06-21 1992-03-10 Chiron Corporation Production of glucose oxidase in recombinant systems
AU3243199A (en) * 1998-03-05 1999-09-20 University Of British Columbia, The Methods for assaying type iii secretion inhibitors
EA200701211A1 (ru) * 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
JP2008133206A (ja) * 2006-11-28 2008-06-12 Yokohama City Univ 緑膿菌に対して感染防御能を誘導できる医薬組成物
KR101491867B1 (ko) * 2007-01-31 2015-02-10 피페넥스 인크. 증가된 발현을 위한 박테리아 리더 서열
EP2220117A2 (en) * 2007-11-30 2010-08-25 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa
EP2408475B1 (en) * 2009-03-18 2017-11-15 Wake Forest University Health Sciences Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa
EP2515935A4 (en) 2009-12-22 2013-08-28 Kalobios Pharmaceuticals Inc METHOD FOR TREATING STAPHYLOCOCCUS INFECTION IN A PATIENT WITH PSEUDOMONAS AERUGINOSA INFECTION WITH LOW PATHOGEN LEVEL
CN103270047A (zh) * 2010-12-23 2013-08-28 因特塞尔奥地利股份公司 Oprf/i剂及其在住院患者和其他患者中的用途
WO2013070565A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
CA2854817C (en) * 2011-11-07 2022-08-16 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
CN104144945A (zh) * 2012-03-02 2014-11-12 埃博灵克斯股份有限公司 结合铜绿假单胞菌pcrv的单可变结构域抗体
US20150284450A1 (en) 2012-11-06 2015-10-08 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules

Also Published As

Publication number Publication date
BR112017023378A2 (pt) 2018-07-24
EP3288974B1 (en) 2020-11-04
US20190345235A1 (en) 2019-11-14
EP3288974A4 (en) 2018-10-24
CN107922482A (zh) 2018-04-17
HK1250991A1 (zh) 2019-01-18
ES2846881T3 (es) 2021-07-30
US10745466B2 (en) 2020-08-18
CA2984628C (en) 2023-09-05
RU2017141738A (ru) 2019-06-03
IL255329A0 (en) 2017-12-31
US10344078B2 (en) 2019-07-09
JP6966330B2 (ja) 2021-11-17
KR20180020142A (ko) 2018-02-27
AU2016257751A1 (en) 2017-11-16
WO2016179101A3 (en) 2016-12-15
IL255329B (en) 2021-09-30
EP3288974A2 (en) 2018-03-07
CA2984628A1 (en) 2016-11-10
RU2017141738A3 (es) 2020-05-22
WO2016179101A2 (en) 2016-11-10
RU2759949C2 (ru) 2021-11-19
JP2018515083A (ja) 2018-06-14
AU2016257751B2 (en) 2021-01-21
ZA201707404B (en) 2021-06-30
US20160318996A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
EA201991157A1 (ru) Доставка белков на основе бактерий, аттенуированных по вирулентности
EP4327885A3 (en) Antibody constructs for msln and cd3
MA44322A (fr) Compositions comprenant des souches bactériennes
EA201791485A1 (ru) Анти-cd47-антитела и их применения
MA42471A (fr) Compositions comprenant des souches bactériennes
SG10201803042PA (en) Anti-tim-3 antibodies
EP4219562A3 (en) Antibody constructs for flt3 and cd3
EA201890315A1 (ru) Молекулы антител, связывающие cd22
EP4276116A3 (en) Bispecific antibody constructs for cdh3 and cd3
WO2015109124A3 (en) Immunomodulatory agents
PH12016501366A1 (en) Novel anti-baff antibodies
WO2012109624A3 (en) Monovalent and multivalent multispecific complexes and uses thereof
WO2014145958A3 (en) Network-based microbial compositions and methods
EP3486256A3 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
PH12019500571A1 (en) Anti-pd-1 antibodies
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
PH12014502179B1 (en) Ang2-binding molecules
PH12015502126A1 (en) Human pac1 antibodies
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
WO2016014612A3 (en) Compositions and methods for the diagnosis of rheumatoid arthritis
MX2017014002A (es) Moléculas de direccionamiento del sistema de secreción tipo iii .
EA201591808A1 (ru) Композиции и способы лечения грибковых и бактериальных патогенов
WO2017002049A3 (en) Conserved chaperone domain for type vi secretion system
WO2018071504A3 (en) Methods of treating diseases with il-23a antibody